

PATENT CASE: DX01342

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Homey et al.

Examiner: Elizabeth Kemmerer

For: Uses of Mammalian Genes

Group Art Unit: 1646

and Related Reagents

Serial No.: 09/995,534

RECEIVED

Filing Date: November 27, 2001

May 7, 2003

MAY 1 2 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

This is in response to the Office Action, Paper No. 9, (Confirmation No. 2027) dated April 9, 2003, in the above-identified application, for which a response is due May 9, 2003.

Restriction requirement

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 10, 13, 14, and 16-26 (all in part), drawn to a methods for treating wounds comprising administering lymphotactin polypeptide, classified in 424, subclass 85.1.
- II. Claims 10 (in part), 13 (in part), 14 (in part), 15, and 16-26 (in part), drawn to a methods for treating wounds comprising administering lymphotactin nucleic acids, classified in 514, subclass 44.

Response

In response to the present Restriction Requirement, Applicants elect <u>Group I</u> (Claims 10, 13, 14 and 16-26, all in part) with <u>traverse</u>. These claims are directed to methods for treating wounds comprising administering a cytokine <u>polypeptide</u> to accelerate wound healing. As noted in Applicants' February 26, 2003 communication, Applicants had selected <u>lymphotactin</u> among the species of cytokines and cytokine receptors listed by the Examiner in the Office Action, Paper No. 6, dated January 15, 2003.

Although the two groups noted above identify inventions that are independent and distinct, Applicants believe that they are sufficiently related to be examined together without causing undue burden to the Examiner. Both groups are drawn to protein delivery. Group I is directed to delivery of lymphotactin polypeptide. Group II is directed to administration of a nucleic acid that expresses lymphotactin polypeptide. As Group II inherently involves the delivery of lymphotactin polypeptide, Applicants believe it would not be a serious burden for the Examiner to examine Group I together with Group II.

According to MPEP §803, there are two criteria for a proper Restriction Requirement:

- (1) the invention must be independent or distinct as claimed, and
- (2) there must be a serious burden on the examiner if the restriction is not required.

 Moreover,

if the search and examination of an entire application can be made without serious burden, the examiner must examine it on the merits, even though it includes claims to distinct or independent inventions.

In conclusion, Applicants respectfully request reconsideration and withdrawal of this Restriction Requirement. Furthermore, Applicants believe that the next step in the prosecution of this Application should be in the form of a Notice of Allowance and respectfully solicit such action.

-3-

If the Examiner has any questions regarding this response, she is encouraged to contact the undersigned.

Respectfully submitted,

SCHERING-PLOUGH CORPORATION Patent Department, K-6-1, 1990 2000 Galloping Hill Road

Kenilworth, New Jersey 07033-0530

Fax: 908-298-5388

Sandy Zaradic, Ph.D. Reg. No. 45,997

Patent Agent for Applicants

(908) 298-7221

SP	164	6
----	-----	---

PTO/SB/21 (03-03)

3C64 JULY		U.S. Pater	Approved for use through 04/30/2003. OMB 0651- int and Trademark Office; U.S. DEPARTMENT OF COMME	RCE	
TRANSMIT FORM	on Act of 1995, no person	Application Number	ion of information unless it displays a valid OMB control nun 09/995,534	Nei.	
RANSMIT	TAL	Filing Date	November 27, 2001		
FORM		First Named Inventor	Homey et al.		
used for all corresponder	nce after initial filing)	Art Unit	1646		
	•	Examiner Name			
		Attorney Docket Number	Elizabeth Kemmerer	\longrightarrow	
Total Number of Pages in This S	Submission 5	Attorney Booket Hamber	DX01342	ノ	
	ENCLOSURES (Check all that apply)				
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declar Extension of Time Requestion Express Abandonment Information Disclosure S Certified Copy of Priority Document(s) Response to Missing Palncomplete Application Response to Misunder 37 CFR 1	ration(s) uest Request Statement y arts/ ssing Parts	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addr Terminal Disclaimer Request for Refund CD, Number of CD(s)	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Certificate of Mailing - 1 page Return Postcard MAY 1 2 200 TECH CENTER 160	03.	
	SIGNATURE C	OF APPLICANT, ATTORN	IEY, OR AGENT		
Signature 80					
I hereby certify that this corresponde first class mail in an envelope addres	ence is being facsimile tra	CATE OF TRANSMISSION Insmitted to the USPTO or deposited were Patents, Washington, DC 20231 on the second	with the United States Postal Service with sufficient postage	as	
Typed or printed				\dashv	
Signature			Date	\neg	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Attorney Docket No.: DX01342 Application No.: 09/995,534


Filing Date: November 27, 2001

PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RECEIVED

MAY 1 2 2003

TECH CENTER 1600/2900

on___May 7, 2003

Date

SANDY ZARADIC, Reg. No. 45,997

Typed or printed name of person of signing Certificate

Signature

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents submitted:

Response Transmittal - 1 page

Response to Restriction Requirement - 3 pages

Certificate of Mailing - 1 page

Return Postcard

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.